Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain
- PMID:25083261
- PMCID: PMC4110876
- DOI: 10.1177/2042098613505614
Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain
Abstract
Used mainly for the management of neuropathic pain, pregabalin is a gabapentinoid or anticonvulsant that was initially developed as an antiepileptic agent. After more than a decade of experience with pregabalin, experience and studies have shown that the adverse effect profile of pregabalin is well tolerated for the management of neuropathic pain and other conditions. Its use is associated with benign central nervous system and systemic adverse effects, and there are very limited metabolic, idiosyncratic or known teratogenic adverse effects. Along with its efficacy in particular neuropathic pain conditions, pregabalin's safety led it to be one of the first pharmacotherapies considered for the management of neuropathic pain. This review discusses the use of pregabalin as well as its potential adverse effects, including the most commonly noted features of sedation, dizziness, peripheral edema and dry mouth. Although other adverse effects may occur, these appear to be uncommon. The review also discusses the clinical implications of pregabalin's use for the clinician.
Keywords: adverse effects; anticonvulsant drugs; epilepsy; neuropathic pain; pregabalin; review; safety.
Conflict of interest statement
Similar articles
- Drug safety evaluation of pregabalin.Toth C.Toth C.Expert Opin Drug Saf. 2012 May;11(3):487-502. doi: 10.1517/14740338.2012.677026. Epub 2012 Apr 3.Expert Opin Drug Saf. 2012.PMID:22468635Review.
- Pregabalin: a new neuromodulator with broad therapeutic indications.Shneker BF, McAuley JW.Shneker BF, et al.Ann Pharmacother. 2005 Dec;39(12):2029-37. doi: 10.1345/aph.1G078. Epub 2005 Nov 15.Ann Pharmacother. 2005.PMID:16288079
- Pregabalin: an antiepileptic agent useful for neuropathic pain.Blommel ML, Blommel AL.Blommel ML, et al.Am J Health Syst Pharm. 2007 Jul 15;64(14):1475-82. doi: 10.2146/ajhp060371.Am J Health Syst Pharm. 2007.PMID:17617497Review.
- Pregabalin for neuropathic pain in adults.Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA.Derry S, et al.Cochrane Database Syst Rev. 2019 Jan 23;1(1):CD007076. doi: 10.1002/14651858.CD007076.pub3.Cochrane Database Syst Rev. 2019.PMID:30673120Free PMC article.
- Antiepileptic drugs for chronic non-cancer pain in children and adolescents.Cooper TE, Wiffen PJ, Heathcote LC, Clinch J, Howard R, Krane E, Lord SM, Sethna N, Schechter N, Wood C.Cooper TE, et al.Cochrane Database Syst Rev. 2017 Aug 5;8(8):CD012536. doi: 10.1002/14651858.CD012536.pub2.Cochrane Database Syst Rev. 2017.PMID:28779491Free PMC article.Review.
Cited by
- Pregabalin for Refractory Radicular Leg Pain due to Lumbar Spinal Stenosis: A Preliminary Prospective Study.Orita S, Yamashita M, Eguchi Y, Suzuki M, Inoue G, Miyagi M, Watanabe T, Ozawa T, Kamoda H, Ishikawa T, Aoki Y, Ito T, Kubota G, Suzuki M, Yamauchi K, Hanaoka E, Sakuma Y, Shimbo J, Oikawa Y, Suzuki T, Takahashi K, Ohtori S.Orita S, et al.Pain Res Manag. 2016;2016:5079675. doi: 10.1155/2016/5079675. Epub 2016 Mar 29.Pain Res Manag. 2016.PMID:27445615Free PMC article.
- Molecular Basic of Pharmacotherapy of Cytokine Imbalance as a Component of Intervertebral Disc Degeneration Treatment.Shnayder NA, Ashkhotov AV, Trefilova VV, Nurgaliev ZA, Novitsky MA, Petrova MM, Narodova EA, Al-Zamil M, Chumakova GA, Garganeeva NP, Nasyrova RF.Shnayder NA, et al.Int J Mol Sci. 2023 Apr 22;24(9):7692. doi: 10.3390/ijms24097692.Int J Mol Sci. 2023.PMID:37175399Free PMC article.Review.
- Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials.Alorfi NM.Alorfi NM.Front Pharmacol. 2022 Sep 23;13:1017129. doi: 10.3389/fphar.2022.1017129. eCollection 2022.Front Pharmacol. 2022.PMID:36210856Free PMC article.Review.
- Pregabalin-Induced Bullous Pemphigoid: A Case Report of a Rare Drug-Triggered Autoimmune Skin Disorder.Tovar R, Jones DT, Srinivasmurthy R, Pandit M, Ho L.Tovar R, et al.Cureus. 2024 Sep 18;16(9):e69649. doi: 10.7759/cureus.69649. eCollection 2024 Sep.Cureus. 2024.PMID:39296925Free PMC article.
- Pregabalin on Hdac2 and Inpp5f levels in rats with CCI-induced neuropathic pain.Yuan L, Li T, Wan Y, Liu Y, Zhou X, Liu C.Yuan L, et al.Exp Ther Med. 2019 Feb;17(2):1300-1305. doi: 10.3892/etm.2018.7037. Epub 2018 Nov 30.Exp Ther Med. 2019.PMID:30680006Free PMC article.
References
- Achar A., Chatterjee G., Ray T., Naskar B. (2010) Comparative study of clinical efficacy with amitriptyline, pregabalin, and amitriptyline plus pregabalin combination in postherpetic neuralgia. Indian J Dermatol Venereol Leprol 76: 63–65 - PubMed
- Anonymous (2005) Pregabalin: new drug. Very similar to gabapentin. Prescrire Int 14: 203–206 - PubMed
- Arif H., Buchsbaum R., Weintraub D., Koyfman S., Salas-Humara C., Bazil C., et al. . (2007) Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68: 1701–1709 - PubMed
- Arnold L., Russell I., Diri E., Duan W., Young J., Jr, Sharma U., et al. . (2008) A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9: 792–805 - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources